These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 18663234)
1. Approaches to treatment of type 2 diabetes. Bloomgarden ZT Diabetes Care; 2008 Aug; 31(8):1697-703. PubMed ID: 18663234 [No Abstract] [Full Text] [Related]
2. Non-alcoholic fatty liver disease and type 2 diabetes: Importance of glycemic control. Bloomgarden Z J Diabetes; 2017 Aug; 9(8):722-723. PubMed ID: 28513098 [No Abstract] [Full Text] [Related]
3. Glycated haemoglobin does not accurately predict average capillary glucose in non insulin-treated type 2 diabetes: The PRISMA study experience. Trevisan R; Bonizzoni E; Bosi E; Ceriello A; Cucinotta D; Giorgino F; Tiengo A; Scavini M Nutr Metab Cardiovasc Dis; 2016 Feb; 26(2):169-70. PubMed ID: 26803592 [No Abstract] [Full Text] [Related]
4. Home glucose monitoring makes little difference in type 2 diabetes. J Fam Pract; 2005 Nov; 54(11):936. PubMed ID: 16299946 [No Abstract] [Full Text] [Related]
6. Clinical markers associated with glycaemic response to dipeptidyl peptidase-4 inhibitor therapy. Yamagishi SI Diabetes Metab Res Rev; 2018 Oct; 34(7):e3024. PubMed ID: 29763999 [No Abstract] [Full Text] [Related]
7. [Preventing infarct in the diabetic patient. Lowering blood glucose and HbA1c are not enough]. Reblin T; Seidel D; Stein D; Görtz A; Lander T MMW Fortschr Med; 2003 May; 145(19):41. PubMed ID: 12813977 [No Abstract] [Full Text] [Related]
8. Assessment of glycaemic control in patients with diabetes mellitus on insulin therapy. Mukherjee JJ; Majumdar S; Ray S J Indian Med Assoc; 2013 Nov; 111(11):761-5. PubMed ID: 24968486 [No Abstract] [Full Text] [Related]
9. Glycaemic efficacy of canagliflozin is largely independent of baseline β-cell function or insulin sensitivity. Matthews DR; Zinman B; Tong C; Meininger G; Polidori D Diabet Med; 2016 Dec; 33(12):1744-1747. PubMed ID: 26600115 [No Abstract] [Full Text] [Related]
10. Case study 1: exploring the pharmacologic agents for treatment of type 2 diabetes. Martin CL Diabetes Educ; 2007; 33 Suppl 1():6S-13S. PubMed ID: 17272803 [No Abstract] [Full Text] [Related]
11. Early insulin treatment in type 2 diabetes: what are the pros? Meneghini LF Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S266-9. PubMed ID: 19875562 [No Abstract] [Full Text] [Related]
16. Relationship of baseline HbA1c and HbA1c reduction following insulin therapy in Type 2 diabetes. Giugliano D; Esposito K Diabet Med; 2011 Feb; 28(2):247. PubMed ID: 21219438 [No Abstract] [Full Text] [Related]
17. How do we gauge the success of treatment of diabetes? Zimmet P; Bloomgarden ZT J Diabetes; 2012 Sep; 4(3):193-4. PubMed ID: 22727202 [No Abstract] [Full Text] [Related]
18. Back to glycemic control: An alternative look at the results of cardiovascular outcome trials in type 2 diabetes. Mannucci E; Monami M; Ceriello A; Rotella CM Nutr Metab Cardiovasc Dis; 2017 Apr; 27(4):375-377. PubMed ID: 28242233 [No Abstract] [Full Text] [Related]
19. Pivotal role of timely basal insulin replacement after metformin failure in sustaining long-term blood glucose control at a target in type 2 diabetes. Bolli GB; Lucidi P; Porcellati F; Fanelli CG Diabetes Care; 2011 May; 34 Suppl 2(Suppl 2):S220-4. PubMed ID: 21525459 [No Abstract] [Full Text] [Related]
20. Clinical practice. Glycemic management of type 2 diabetes mellitus. Ismail-Beigi F N Engl J Med; 2012 Apr; 366(14):1319-27. PubMed ID: 22475595 [No Abstract] [Full Text] [Related] [Next] [New Search]